Related Experiment Video
Updated: Jul 12, 2026
13:04
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Treating viral hepatitis C: efficacy, side effects, and complications
M P Manns1, H Wedemeyer, M Cornberg
1Department of Gastroenterology, Hepatology, and Endocrinology, Medical School of Hannover, Carl-Neuberg-Str 1, D-30625 Hannover, Germany. manns.michael@mh-hannover.de
Gut
|August 15, 2006
Summary
Hepatitis C treatment has advanced, offering cures for many. However, current interferon and ribavirin therapies have limitations, especially for Hepatitis C Virus (HCV) genotype 1, driving the need for new approaches.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Chronic Hepatitis C Virus (HCV) infection is a significant global health concern.
- Recent advancements have led to curative treatments for a substantial number of patients.
- Current standard therapy involves pegylated interferon alpha and ribavirin.
Purpose of the Study:
- To review the efficacy and optimization of current Hepatitis C treatments.
- To discuss the limitations and challenges of standard therapy.
- To explore emerging therapeutic strategies beyond interferon-based treatments.
Main Methods:
- Literature review of current Hepatitis C treatment guidelines and research.
- Analysis of efficacy data for standard therapy in different patient populations.
- Examination of side effect profiles and patient-specific challenges.
- Overview of novel therapeutic agents and future directions.
Main Results:
- Hepatitis C treatment has shown dramatic improvement, with a significant cure rate.
- Pegylated interferon alpha and ribavirin, the standard therapy, exhibit limitations.
- Efficacy is notably reduced in patients with Hepatitis C Virus (HCV) genotype 1.
- The side effect profile of current therapy necessitates alternative approaches.
Conclusions:
- While curative, current standard Hepatitis C therapy has significant drawbacks.
- New therapeutic strategies are essential to overcome limitations in efficacy and tolerability.
- The future of Hepatitis C treatment lies in novel, interferon-free approaches.
Related Concept Videos
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...